Home  |  How It Works  |  Results  |  All Reports  |  Latest

πŸ“ˆ Testing Results

14 years of πŸ† SPOTLIGHT & βœ… OPPORTUNITY signals, backtested against the S&P 500.
Real numbers, no cherry-picking, every signal counted.

+361.2% Total return
+174.5% Alpha vs S&P 500
56 Unique stocks picked
71% Win rate

Scoring model R29  Β·  3,446 daily screening dates  Β·  2011–2025  Β·  Version history β†’

The Test

We took every unique πŸ† SPOTLIGHT & βœ… OPPORTUNITY signal generated by our pipeline from 2012 to 2025 and invested a hypothetical $100 in each stock at its first recommendation price. No second chances, no averaging in. If the screener flagged it, we bought it and held.

Then we did the same with the S&P 500: $100 into SPY on each of those same 56 dates. Same capital, same timing, different picks. The only variable is what the screener chose versus the market index.

Head-to-Head: Our Picks vs the S&P 500

Metric Jumpstart Signal S&P 500 (SPY)
Total invested $5,600 $5,600
Value (Feb 2026) $25,827 $16,052
Profit / Loss +$20,227 +$10,452
Total return +361.2% +186.7%
Excess return (alpha) +174.5% above SPY

Values priced as of 2026-02-01 (February 2026). SPY exit price: $691.97.

In this backtest, for each of the 56 unique stocks our screener flagged, we simulated a $100 purchase at the first signal price and a simultaneous $100 purchase of SPY on that same date. Same hypothetical capital, same timing, same number of trades, the only variable was what was bought. Held to February 2026, the screener's picks produced $9,774 more than the index would have.

πŸ’‘ What if you bought every signal, not just the first?
The figure above reflects one $100 investment per unique ticker, the most conservative measure. When we simulate buying $100 on every recommendation entry across 14 years (209 total entries, including repeat appearances by the same stock), the excess return rises to +260.6% above SPY. Stocks that stayed in our screener longest, NVDA, ANET, AAPL, contributed multiple winning entries. The first-entry figure (+174.5%) is the headline because it's the most conservative and auditable; the all-entries figure illustrates the potential range of outcomes for someone who evaluated and acted on each signal as it arrived, past results that depended heavily on a handful of multi-year compounders and won't necessarily repeat.

Why This Matters

Most active stock-picking strategies fail to beat the S&P 500. Studies consistently show that fewer than 40% of actively managed funds outperform their benchmark in any given year, and over 10-15 year periods that number drops below 15%.

Our pipeline delivered +361.2% across 56 stock picks spanning 14 years of bull markets, bear markets, COVID crashes, rate hikes, and sector rotations. It didn't just keep up with the index. It pulled ahead.

14yr Backtest window
209 Total entries
40 Winners
16 Losers

Top Performers

These are the 10 best-returning stocks from our πŸ† SPOTLIGHT + βœ… OPPORTUNITY signals, bought at their first recommendation price:

Ticker First Signal Entry Feb 2026 Return
NVDA Jan 3, 2018 $5.25 $191.13 +3,541%
ANET Nov 7, 2016 $5.37 $141.74 +2,540%
CDNS Mar 15, 2012 $12.40 $296.36 +2,290%
AAPL Jan 4, 2012 $12.39 $259.24 +1,992%
URI Apr 18, 2012 $45.75 $782.06 +1,609%
IDXX Apr 19, 2012 $44.09 $670.46 +1,421%
MANH Feb 10, 2012 $11.41 $151.01 +1,224%
TYL Jan 23, 2012 $34.38 $369.40 +974%
RGEN Jan 22, 2014 $14.13 $149.37 +957%
TTWO Nov 7, 2014 $26.16 $220.30 +742%

The Losing Picks

We show our losers too. Not every pick works out, and transparency matters more than marketing. Here are the 10 worst-performing πŸ† SPOTLIGHT + βœ… OPPORTUNITY signals:

Ticker First Signal Entry Feb 2026 Return
BL Mar 13, 2024 $68.03 $46.47 -32%
FOXF Mar 1, 2017 $27.15 $18.40 -32%
TBCH Oct 23, 2020 $19.30 $11.96 -38%
PAYO Jan 16, 2025 $10.73 $6.39 -40%
IMXI Oct 24, 2022 $26.67 $15.46 -42%
IMMR May 22, 2018 $12.94 $6.72 -48%
AOSL Mar 2, 2022 $53.39 $22.10 -59%
MYGN Apr 30, 2012 $26.01 $5.62 -78%
ZDGE Mar 19, 2021 $15.28 $3.11 -80%
MX Mar 4, 2021 $21.65 $2.90 -87%

Even with these losses factored in, the portfolio still beat the S&P 500. The winners more than covered the losers: 40 stocks finished positive against 16 that finished negative.

Stocks We Missed

Not every great stock passes our filters, and we show that transparently. These well-known stocks never received a SPOTLIGHT or OPPORTUNITY signal:

⚠️ Important: These backtest scores do not include sentiment points. In the live pipeline, Stage 4 adds up to 10 points from AI-powered news sentiment analysis. NFLX peaked at 69/100 in the backtest, a neutral-to-positive sentiment score (5–10 points) would have pushed it past the 70-point OPPORTUNITY threshold on multiple dates. Sentiment scoring was not available historically, so these near-misses may convert to signals in live screening.

Missing these stocks is the cost of the discipline that produces a 71% win rate across the full portfolio. See all case studies β†’

What Drives the Edge

Our pipeline doesn't predict the future. It stacks probabilities in your favour by combining multiple validated signals:

Methodology

How this backtest was constructed

What 14 Years of Testing Taught Us

Case Studies

Hand-picked SPOTLIGHT stories: when our system flagged each ticker, what it returned, and the lesson behind the signal.

NVDA πŸ†
NVIDIA Corporation Caught 27 times between 2018 and 2024
ANET πŸ†
Arista Networks Caught 15 times between 2016 and 2024
ICLR πŸ†
ICON plc Caught 7 times between 2015 and 2017
⚠️ Important: Past performance does not guarantee future results. This is a hypothetical backtest, not a live trading record. Real-world results would differ due to commissions, slippage, taxes, and the inability to perfectly replicate historical signals. The backtest assumes buy-and-hold with no risk management, which most investors would not follow in practice. Always do your own research before investing.

Get Daily Advanced Signals Free

Actionable and freshly screened US πŸ‡ΊπŸ‡Έ stocks in your inbox every trading day.

Your subscription could not be saved. Please try again.
Your subscription has been successful.